Related Experiment Video

Updated: Jun 18, 2026

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance

Nicolas Dzamko1, Bryce J W van Denderen, Andrea L Hevener

  • 1Department of Medicine, St Vincent's Institute of Medical Research, University of Melbourne, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia.

The Journal of Biological Chemistry
|November 7, 2009
PubMed

Insights

AMP-activated protein kinase (AMPK) beta1 knockout mice exhibit reduced appetite and body mass. This AMPK deficiency protects against diet-induced obesity, insulin resistance, and hepatic steatosis.

Area of Science:

  • Metabolic regulation
  • Obesity research
  • Biochemistry

Background:

  • AMP-activated protein kinase (AMPK) is a key regulator of cellular energy homeostasis and fuel metabolism.
  • AMPK functions as an alpha-beta-gamma heterotrimer, with diverse roles in appetite and metabolic control.

Purpose of the Study:

  • To investigate the physiological role of the AMPK beta1 subunit in vivo.
  • To determine the impact of beta1 subunit deficiency on appetite, body mass, and diet-induced metabolic dysfunction.

Main Methods:

  • Generation of AMPK beta1 knockout (beta1(-/-)) mice on a C57Bl/6 background.
  • Assessment of AMPK activity in various tissues (liver, hypothalamus, white adipose tissue, skeletal muscle, heart).
  • Evaluation of metabolic parameters, including food intake, body mass, adiposity, metabolic rate, physical activity, and diet-induced insulin resistance and hepatic steatosis.

Main Results:

  • Beta1(-/-) mice were viable, fertile, and exhibited no overt developmental defects.
  • A 90% reduction in hepatic AMPK activity was observed in beta1(-/-) mice, with modest reductions in the hypothalamus and white adipose tissue.
  • Beta1(-/-) mice showed reduced food intake, adiposity, and total body mass on both low-fat and high-fat diets, with protection from diet-induced hyperinsulinemia, hepatic steatosis, and insulin resistance.

Conclusions:

  • Loss of the AMPK beta1 subunit significantly reduces food intake and body mass.
  • AMPK beta1 deficiency confers protection against the adverse metabolic consequences of a high-fat diet, highlighting its critical role in regulating appetite and preventing obesity-related diseases.

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...